Tysabri and PML: Understanding the Safety Concerns in North Carolina

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specialized Risk Awareness

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Understanding the symptoms and monitoring protocols is crucial for early detection. The legacy of medical research has long emphasized the need for careful risk-benefit analysis in biologic therapies, and this page reviews the reported patterns of PML in Tysabri patients to help you stay informed.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). The FDA-approved prescribing information includes a boxed warning stating that TYSABRI increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning identifies three key risk factors: the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold TYSABRI immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. The duration of Tysabri treatment before PML onset can range from a few months to several years, as noted in the prescribing information for herpes infections, though similar latency applies to PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FAERS adverse-event reports list PML-related symptoms such as cognitive disorder (3478 reports), memory impairment (7895 reports), gait disturbance (9422 reports), and balance disorder (5621 reports) among the most frequently associated events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Statute of Limitations for Tysabri Claims in North Carolina

For patients in North Carolina who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability claim. North Carolina's statute of limitations for personal injury actions is generally three years from the date the injury is discovered or should have been discovered with reasonable diligence. For PML, the discovery date may be when a physician confirms the diagnosis via MRI and CSF analysis, or when symptoms become clearly attributable to the drug. Given the latency between Tysabri exposure and PML onset, patients and their families should document the timeline of treatment initiation, duration, and symptom emergence. The adequacy of warnings is a central issue: the boxed warning explicitly states that TYSABRI increases PML risk and lists risk factors, but plaintiffs may argue that the warning was insufficient to convey the severity or probability of harm, or that healthcare providers were not adequately educated through the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program requires patient enrollment and acknowledgment of risks, but compliance failures or inadequate risk communication could form the basis of a claim. Attorney considerations for affected patients include gathering medical records that document Tysabri prescription, infusion dates, and any prior immunosuppressant use. Evidence of anti-JCV antibody status and duration of therapy is critical, as these are established risk factors. The timeline between first Tysabri dose and PML diagnosis must be established to demonstrate causation. North Carolina courts may apply the learned intermediary doctrine, which holds that drug manufacturers fulfill their duty to warn by informing prescribing physicians, not patients directly. However, if the manufacturer failed to provide adequate information to physicians about PML risk or the TOUCH program's restrictions, liability may still attach. Patients should consult an attorney experienced in pharmaceutical litigation to assess whether the statute of limitations has been met and to evaluate the strength of a failure-to-warn claim. In summary, Tysabri-associated PML is a devastating condition with a clear mechanistic basis and documented risk factors. North Carolina patients facing this diagnosis must act promptly to preserve legal rights, given the three-year statute of limitations from discovery. The adequacy of warnings and compliance with the TOUCH program are key factual issues that will determine liability. Medical records detailing treatment history and PML diagnosis are essential for both clinical management and legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in North Carolina?

North Carolina's statute of limitations for personal injury actions is generally three years from the date the injury is discovered or should have been discovered with reasonable diligence. For PML, the discovery date is typically when a physician confirms the diagnosis via MRI and CSF analysis, or when symptoms become clearly attributable to the drug. It is crucial to act promptly to preserve legal rights.

What evidence is needed to support a Tysabri PML claim?

Key evidence includes medical records documenting Tysabri prescription and infusion dates, prior immunosuppressant use, anti-JCV antibody status, duration of therapy, and the timeline between first dose and PML diagnosis. Brain MRI and CSF analysis results confirming PML are also essential. This evidence helps establish causation and the adequacy of warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.